(VIANEWS) – The NASDAQ opens in less than one hour and Pacific Biosciences of California‘s pre-market value is already 4.71% down.
Pacific Biosciences of California’s last close was $3.61, 75.19% below its 52-week high of $14.55.
The last session, NASDAQ finished with Pacific Biosciences of California (PACB) jumping 4.64% to $3.61. NASDAQ jumped 0.32% to $16,306.64, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-1.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.53%.
Yearly Top and Bottom Value
Pacific Biosciences of California’s stock is valued at $3.61 at 09:28 EST, below its 52-week low of $4.00.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Pacific Biosciences of California’s EBITDA is 7.44.
Moving Average
Pacific Biosciences of California’s worth is way below its 50-day moving average of $6.68 and way below its 200-day moving average of $9.45.
More news about Pacific Biosciences of California (PACB).
